Sentences with phrase «cell cancer therapies»

Not exact matches

The Food and Drug Administration (FDA) on Tuesday gave Swiss drug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancers.

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

The treatment is a type of so - called CAR T - cell therapy — taking a patient's own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

Gilead subsidiary Kite Pharma (which the biotech giant scooped up ahead of the FDA's approval for Yescarta, a treatment that reengineers patients» immune cells to fight cancer) will have access to Sangamo's platform technology, which could be used to create various types of cancer cell therapies.

About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therapy.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

Swiss pharmaceutical giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases.

And to affect more people, the cell therapies would need to go beyond blood cancers.

The race to become the first company with a chimeric antigen receptor T - cell (CAR - T) cancer therapy on the market has entered its final leg, and Kite Pharma now appears to have a big advantage.

BioNTech, which has around 700 employees at sites in Germany — more than any other unlisted biotech firm in Europe — is also working on other cancer - fighting technologies, including antibodies, cell therapies and small molecules.

In the second half of 2017, the United States Food and Drug Administration (FDA) approved two immunotherapies that use genetically engineered T cells (CAR - T cell therapy) to fight cancer.

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Cambridge, MA — December 21, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $ 30 million Series C financing.

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

Adoptive cell therapy for hard - to - treat blood cancers, after all, are widely expected to be the standard of care within a decade, and it should therefore grow to become one of the most lucrative markets in all of biotech.

For example, we've seen new discoveries in health care recently, especially in immuno - oncology therapies, which help the immune systems of cancer patients recognize and destroy cancerous cells.

Overcoming the immense logistical challenges involved with withdrawing, shipping, modifying, returning, then reinfusing cells for every patient treated paints a scary question mark on the future of cell - based cancer therapies.

Treatment typically involves chemotherapy (using chemicals intravenously to kill cancer cells), radiation therapy (using high - powered X-rays to kill cancer cells), or surgery to remove the breast and surrounding lymph nodes.

Anti-hormone therapy is a commonly prescribed treatment for cancer of the prostate, which helps to reduce the levels of male hormones — that stimulate cancer cells to grow — in the gland.

Disney said the precise binding of Targapremir - 18a to microRNA - 18a means a cancer drug that follows this strategy would be likely to kill prostate cancer cells without causing the broader side effects seen with many other cancer therapies.

The triggering of PARP enables cancer cells to withstand anti-hormone therapy treatment, causing cells to cultivate and develop into a more aggressive form.

During the sessions, U.S. and Cuban scientists explored such topics as the molecular mechanisms cancer cells employ to evade the body's immune system, new tools to image and manipulate that system, and ways to rethink how such therapies can best be deployed to reach patients where they receive health services.

A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.

Non — small cell lung cancer may involve genetic aberrations that can be used to direct therapy.

The new treatments, called CAR T cell therapies, eliminate cancer using people's own cells.

He predicts that the United States Food and Drug Administration will approve CAR T cell therapies for cancer this year.

Currently, most cancer therapy relies on frontal assaults on malignant cells.

«Used in cancer therapy, this process could increase the impact of a treatment by heating the cancer cells while introducing the drug compound into the tumor.»

A type of immune therapy known as PD - 1 blockade controlled cancer in 77 percent of patients with defects in DNA mismatch repair — the system cells use to spell - check and fix errors in DNA (SN Online: 10/7/15).

Even more applications for cell therapies beyond cancer could become reality in the coming years.

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)- T cells to meet surging demand.

CAR - T cell therapy took the cancer world by storm in the summer of 2010.

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

A route used by tumor cells to spread could be exploited to make stem cells for regenerative medicine and cancer therapies

While the combination therapies block off the principal pathway that cancer cells use to fuel their growth, the cells come to bypass this blockade and, like vehicles on a detour route, make use of additional pathways to continue growing and spreading.

A new study has identified a group of molecules in prostate - cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

Sutherland says the genes she studies are already silenced in healthy adult tissue, so theoretically researchers should be able to design therapies that re-silence them in cancer cells without side effects.

All are examples of translational researchers converting molecular knowledge about specific cancer cells into effective, targeted therapies.

The findings inject hard facts into a debate that has long divided the medical community, with many radiation oncologists preferring adjuvant therapy — radiation given soon after prostate removal to kill off any remaining cancer cells — and many urologists preferring salvage therapy — radiation given later, when prostate - specific antigen tests suggest it's needed.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

In the GD2 CAR - T treated animals, the residual cancer cells did not express GD2, suggesting that these remaining cells were not vulnerable to the immune therapy and might be able to cause the cancer to recur.

«Fibroblast growth factor receptor inhibitors are new therapies being developed in clinical trials for patients whose cancer cells have genetic alterations in this family of genes,» says Roychowdhury, a member of the OSUCCC — James Translational Therapeutics Program.